Gyre Therapeutics, Inc. (GYRE)
NASDAQ: GYRE · Real-Time Price · USD
7.56
-0.11 (-1.43%)
Apr 29, 2026, 11:47 AM EDT - Market open
Gyre Therapeutics Revenue
In the year 2025, Gyre Therapeutics had annual revenue of $116.59M with 10.24% growth. Gyre Therapeutics had revenue of $37.20M in the quarter ending December 31, 2025, with 33.45% growth.
Revenue (ttm)
$116.59M
Revenue Growth
+10.24%
P/S Ratio
6.01
Revenue / Employee
$186,541
Employees
625
Market Cap
690.33M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 116.59M | 10.83M | 10.24% |
| Dec 31, 2024 | 105.76M | -7.69M | -6.78% |
| Dec 31, 2023 | 113.45M | 11.16M | 10.91% |
| Dec 31, 2022 | 102.29M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionGYRE News
- 6 weeks ago - Gyre Therapeutics Announces China's NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment - GlobeNewsWire
- 6 weeks ago - Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Gyre Therapeutics Enters into Agreement to Acquire Cullgen to Gain Targeted Protein Degradation Platform and Pipeline - GlobeNewsWire
- 4 months ago - Gyre Therapeutics Announces Alignment with China's CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA Meeting - GlobeNewsWire
- 6 months ago - Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update - GlobeNewsWire
- 7 months ago - Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis - GlobeNewsWire
- 7 months ago - Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025 - GlobeNewsWire
- 8 months ago - Gyre Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference - Transcripts